

Regimen Reference Order – MYEL – lenalidomide + dexamethasone

ARIA: MYEL - [lenalidomide + dexamethasone (1st Line)]

Planned Course: Every 28 days until disease progression or unacceptable toxicity

Indication for Use: Multiple Myeloma Transplant Ineligible – First Line Treatment

Proceed with treatment if:

ANC equal to or greater than $1 \times 10^9/L$ AND Platelets equal to or greater than $30 \times 10^9/L$

❖ Contact prescribing hematologist if parameters not met

SEQUENCE OF MEDICATION ADMINISTRATION

Treatment Regimen – LYMP – lenalidomide

Drug	Dose	Quantity of drug to be dispensed
lenalidomide*	25 mg	Orally once daily Days 1 to 21 (Self-administered at home)
dexamethasone	40 mg	Orally once daily Days 1, 8, 15 and 22 (Self-administered at home)

*lenalidomide (Revlimid®) available dosage strengths: 5 mg, 10 mg, 15 mg, 20 mg and 25 mg capsules

*Classification: Cytotoxic Hazardous

REQUIRED MONITORING

Day 1

- CBC, creatinine, calcium, albumin, random glucose, LFTs, SPEP/FLCI (response assessment) and TSH as per physician order

Day 15 (required for the first 4 cycles)

- CBC as per physician order

Per RevAid program – See Additional Information

- Monthly β HCG and RevAid survey for women of childbearing potential

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
acetylsalicylic acid (ASA) enteric coated	81 mg delayed release	Orally once daily

DISCHARGE INSTRUCTIONS

- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- Patients should be prescribed an antiplatelet agent (or anticoagulation if high risk) to prevent blood clots on lenalidomide. The majority of patients will be prescribed acetylsalicylic acid (ASA) enteric coated 81 mg once daily. Patients at high risk may be prescribed other anticoagulants instead of acetylsalicylic acid.
- Lenalidomide is teratogenic
- Female patients of childbearing potential will require monthly pregnancy tests (βHCG) that must be done within 7 days of the next prescription fill
- Lenalidomide is controlled by a distribution program requiring prescriptions to be written by a RevAid registered physician and dispensed by a RevAid registered pharmacy